Can Dolly the sheep bring home the bacon? Roslin Bio-Med has licensed nuclear transfer technology from the Roslin Institute to develop transgenic pigs from which the start-up hopes to obtain organs for transplant and blood products.

Thousands die each year of end-stage organ failure. Transplantation is the preferred therapy, but there is a chronic shortage of human organs and organ rejection remains a problem. Bringing xenotransplantation to market has become a big company affair, but BioTransplant is a biotech still looking to win a piece of the market through an unusual partnership and unique technology.